Literature DB >> 14381516

Cardiovascular and renal responses to the combination of hexamethonium and 1-hydrazinophthalazine (apresoline) in hypertensive subjects.

D H STEIN, H H HECHT.   

Abstract

Entities:  

Keywords:  CARDIOVASCULAR SYSTEM/effect of drugs on; HYPERTENSION/therapy; KIDNEYS/effect of drugs on; MUSCLE RELAXANTS/therapeutic use; SYMPATHOLYTICS/therapeutic use

Mesh：

Substances：

Year:  1955        PMID： 14381516      PMCID： PMC1072617          DOI： 10.1172/JCI103142

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  14 in total

1.  Studies on the control of hypertension by hyphex. I. Effects on blood pressure.

Authors:  H A SCHROEDER; J D MORROW; H M PERRY
Journal:  Circulation       Date:  1953-11       Impact factor: 29.690

2.  Studies on the control of hypertension by hyphex. II. Toxic reactions and side effects.

Authors:  J D MORROW; H A SCHROEDER; H M PERRY
Journal:  Circulation       Date:  1953-12       Impact factor: 29.690

3.  The acute effects of hexamethonium on renal hemodynamics in normotensive and hypertensive human subjects.

Authors:  L C MILLS; J H MOYER
Journal:  Am J Med Sci       Date:  1953-07       Impact factor: 2.378

4.  Hydrallazine (apresoline) hydrochloride; pharmacological observations and clinical results in the therapy of hypertension.

Authors:  J H MOYER
Journal:  AMA Arch Intern Med       Date:  1953-04

5.  Hexamethonium-its effect on glomerular filtration rate, maximal tubular function and renal excretion of electrolytes.

Authors:  J H MOYER; L C MILLS
Journal:  J Clin Invest       Date:  1953-02       Impact factor: 14.808

6.  Effect of hexamethonium chloride on cardiovascular and renal hemodynamics and on electrolyte excretion.

Authors:  J H MOYER; R A HUGGINS; C A HANDLEY; L C MILLS
Journal:  J Pharmacol Exp Ther       Date:  1952-10       Impact factor: 4.030

7.  Some pharmacodynamic effects of 1-hydrazinophthalazine (C-5968) with particular reference to renal function and cardiovascular response.

Authors:  J H MOYER; C A HANDLEY; R A HUGGINS
Journal:  J Pharmacol Exp Ther       Date:  1951-12       Impact factor: 4.030

8.  The effect of 1-hydrazinophthalazine (C-5968) and related compounds on the cardiovascular system of dogs.

Authors:  H A WALKER; S WILSON; E C ATKINS; H E GARRETT; A P RICHARDSON
Journal:  J Pharmacol Exp Ther       Date:  1951-04       Impact factor: 4.030

9.  Clinical evaluation of 1-hydrazinophthalazine (C-5968) in hypertension, with special reference to alternating treatment with hexamethonium.

Authors:  R L JOHNSON; E D FREIS; H W SCHNAPER
Journal:  Circulation       Date:  1952-06       Impact factor: 29.690

10.  Suppression of vasomotor reflexes in man following L-hydrazinophthalozine (C-5968).

Authors:  E D FREIS; F A FINNERTY
Journal:  Proc Soc Exp Biol Med       Date:  1950-10
View more
  4 in total

1.  [Effect of peroral prolonged therapy with 1,4-dihydrazinophthalazine on circulation and reflex changes in dogs].

Authors:  V EHRLICH; K FRONKOVA; L SLEGR
Journal:  Arch Kreislaufforsch       Date:  1958-09

2.  Clinical pharmacokinetics of hydrallazine.

Authors:  T Talseth
Journal:  Clin Pharmacokinet       Date:  1977 Sep-Oct       Impact factor: 6.447

3.  The use of radioactive microspheres to compare the effects of hydralazine, guanethidine and SK & F 24260 on the redistribution of cardiac output in anaesthetized rabbits.

Authors:  B M Johnson
Journal:  Br J Pharmacol       Date:  1975-11       Impact factor: 8.739

4.  Influence of adrenergic beta-receptor blockade on the acute cardiovascular effects of hydralazine.

Authors:  H Brunner; P R Hedwall; M Meier
Journal:  Br J Pharmacol Chemother       Date:  1967-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.